NICE has rejected routine NHS funding for Roche's Evrysdi (risdiplam) for spinal muscular ... price to be provided to the roughly 1,500 people with the rare genetic disorder who might be eligible ...

With Zolegsma costing Rs 17 crore and Risdiplam costing about a crore, it is beyond the reach of both central and state governments as well as the people, stated the letter. Beeran urged for ...